{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T01:12:06Z","timestamp":1792804326493,"version":"4.5.0"},"reference-count":7,"publisher":"MDPI AG","issue":"4","license":[{"start":{"date-parts":[[2022,3,30]],"date-time":"2022-03-30T00:00:00Z","timestamp":1648598400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Canadian Partnership Against Cancer","award":["12208"],"award-info":[{"award-number":["12208"]}],"id":[{"id":"https:\/\/ror.org\/0488wxv90","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Current Oncology"],"abstract":"<jats:p>The COVID-19 pandemic resulted in temporary holds placed on new trial startups, patient recruitment and follow up visits for trials which contributed to major disruptions in cancer center trial unit operations. To assess the impact, the Canadian Cancer Clinical Trials Network (3CTN) members participated in regional meetings and a survey to understand the impact of the pandemic to academic cancer clinical trials (ACCT) activity, cancer trial unit operations and supports needed for post-pandemic recovery. Trial performance and recruitment data collected from 1 April 2020\u201331 March 2021 was compared to the same period in previous years. From 1 April\u201330 June 2020, patient recruitment decreased by 67.5% and trial site activations decreased by 81% compared to the same period in 2019. Recovery to reopening and recruitment of ACCTs began after three months, which was faster than initially projected. However, ongoing COVID-19 impacts on trial unit staffing and operations continue to contribute to delayed trial activations, lower patient recruitment and may further strain centers\u2019 capacity for participation in academic-sponsored trials.<\/jats:p>","DOI":"10.3390\/curroncol29040197","type":"journal-article","created":{"date-parts":[[2022,3,30]],"date-time":"2022-03-30T21:22:14Z","timestamp":1648675334000},"page":"2435-2441","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["The Impact of COVID-19 on Academic Cancer Clinical Trials in Canada and the Initial Response from Cancer Centers"],"prefix":"10.3390","volume":"29","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8275-4767","authenticated-orcid":false,"given":"Stephen","family":"Sundquist","sequence":"first","affiliation":[{"name":"Canadian Cancer Clinical Trials Network, Toronto, ON M5G 0A3, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana","family":"Kato","sequence":"additional","affiliation":[{"name":"Canadian Cancer Clinical Trials Network, Toronto, ON M5G 0A3, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca Y.","family":"Xu","sequence":"additional","affiliation":[{"name":"Canadian Cancer Clinical Trials Network, Toronto, ON M5G 0A3, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Schoales","sequence":"additional","affiliation":[{"name":"Canadian Cancer Clinical Trials Network, Toronto, ON M5G 0A3, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saranya","family":"Kulendran","sequence":"additional","affiliation":[{"name":"Canadian Cancer Clinical Trials Network, Toronto, ON M5G 0A3, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janet E.","family":"Dancey","sequence":"additional","affiliation":[{"name":"Canadian Cancer Clinical Trials Network, Toronto, ON M5G 0A3, Canada"},{"name":"Canadian Cancer Trials Group, Queen\u2019s University, Kingston, ON K7L 3N6, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,3,30]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"2830","DOI":"10.3390\/curroncol28040248","article-title":"Advancing Academic Cancer Clinical Trials Recruitment in Canada","volume":"28","author":"Xu","year":"2021","journal-title":"Curr. Oncol."},{"key":"ref_2","unstructured":"(2020). Annual Report 2019\u20132020, Canadian Cancer Clinical Trials Network."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"71","DOI":"10.3747\/co.27.6643","article-title":"Impact of COVID-19 on Canadian medical oncologists and cancer care: Canadian Association of Medical Oncologists survey report","volume":"27","author":"Gill","year":"2020","journal-title":"Curr. Oncol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1200\/OP.20.00275","article-title":"Early Impact of COVID-19 on the Conduct of Oncology Clinical Trials and Long-Term Opportunities for Transformation: Findings From an American Society of Clinical Oncology Survey","volume":"16","author":"Waterhouse","year":"2020","journal-title":"JCO Oncol. Pract."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1038\/d41573-020-00093-1","article-title":"Impact of COVID-19 on oncology clinical trials","volume":"19","author":"Upadhaya","year":"2020","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.ccell.2021.12.014","article-title":"COVID-19 mRNA booster vaccines elicit strong protection against SARS-CoV-2 Omicron variant in patients with cancer","volume":"40","author":"Zeng","year":"2022","journal-title":"Cancer Cell"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"e374","DOI":"10.1016\/S1470-2045(20)30397-1","article-title":"Disruption of cancer care in Canada during COVID-19","volume":"21","year":"2020","journal-title":"Lancet Oncol."}],"container-title":["Current Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1718-7729\/29\/4\/197\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T22:46:14Z","timestamp":1760136374000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1718-7729\/29\/4\/197"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,30]]},"references-count":7,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2022,4]]}},"alternative-id":["curroncol29040197"],"URL":"https:\/\/doi.org\/10.3390\/curroncol29040197","relation":{},"ISSN":["1718-7729"],"issn-type":[{"value":"1718-7729","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,30]]}}}